T. Rowe Price Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.83B | Buy |
13,003,989
+3,177,601
| +32% | +$705M | 0.33% | 55 |
|
|
2025
Q4 | $2.25B | Sell |
9,826,388
-775,839
| -7% | -$177M | 0.24% | 81 |
|
|
2025
Q3 | $2.45B | Buy |
10,602,227
+1,542,195
| +17% | +$314M | 0.26% | 71 |
|
|
2025
Q2 | $1.68B | Buy |
9,060,032
+1,865,218
| +26% | +$347M | 0.19% | 100 |
|
|
2025
Q1 | $1.51B | Sell |
7,194,814
-2,999,412
| -29% | -$583M | 0.19% | 101 |
|
|
2024
Q4 | $1.81B | Sell |
10,194,226
-63,736
| -0.6% | -$11.7M | 0.21% | 89 |
|
|
2024
Q3 | $2.03B | Sell |
10,257,962
-685,246
| -6% | -$128M | 0.23% | 78 |
|
|
2024
Q2 | $1.88B | Buy |
10,943,208
+199,018
| +2% | +$33M | 0.22% | 84 |
|
|
2024
Q1 | $1.96B | Buy |
10,744,190
+1,291,201
| +14% | +$223M | 0.24% | 85 |
|
|
2023
Q4 | $1.46B | Sell |
9,452,989
-3,361,579
| -26% | -$490M | 0.2% | 109 |
|
|
2023
Q3 | $1.91B | Sell |
12,814,568
-350,146
| -3% | -$51.4M | 0.28% | 70 |
|
|
2023
Q2 | $1.77B | Sell |
13,164,714
-4,411,166
| -25% | -$647M | 0.25% | 76 |
|
|
2023
Q1 | $2.8B | Sell |
17,575,880
-2,847,220
| -14% | -$435M | 0.42% | 48 |
|
|
2022
Q4 | $3.3B | Sell |
20,423,100
-4,098,236
| -17% | -$628M | 0.53% | 40 |
|
|
2022
Q3 | $3.29B | Sell |
24,521,336
-6,286,462
| -20% | -$902M | 0.54% | 38 |
|
|
2022
Q2 | $4.72B | Sell |
30,807,798
-5,924,329
| -16% | -$905M | 0.6% | 24 |
|
|
2022
Q1 | $5.95B | Buy |
36,732,127
+4,146,214
| +13% | +$602M | 0.6% | 24 |
|
|
2021
Q4 | $4.41B | Buy |
32,585,913
+6,377,892
| +24% | +$753M | 0.4% | 41 |
|
|
2021
Q3 | $2.83B | Sell |
26,208,021
-2,791,314
| -10% | -$319M | 0.27% | 82 |
|
|
2021
Q2 | $3.27B | Sell |
28,999,335
-3,212,860
| -10% | -$362M | 0.3% | 64 |
|
|
2021
Q1 | $3.49B | Sell |
32,212,195
-296,222
| -0.9% | -$31.7M | 0.35% | 53 |
|
|
2020
Q4 | $3.48B | Sell |
32,508,417
-231,462
| -0.7% | -$22.2M | 0.36% | 58 |
|
|
2020
Q3 | $2.87B | Sell |
32,739,879
-9,038,901
| -22% | -$851M | 0.33% | 55 |
|
|
2020
Q2 | $4.1B | Sell |
41,778,780
-1,149,050
| -3% | -$101M | 0.52% | 34 |
|
|
2020
Q1 | $3.27B | Buy |
42,927,830
+14,838,316
| +53% | +$1.26B | 0.52% | 31 |
|
|
2019
Q4 | $2.49B | Buy |
28,089,514
+8,310,959
| +42% | +$690M | 0.32% | 64 |
|
|
2019
Q3 | $1.5B | Buy |
19,778,555
+14,602,485
| +282% | +$1B | 0.21% | 114 |
|
|
2019
Q2 | $376M | Buy |
5,176,070
+2,326,510
| +82% | +$183M | 0.05% | 329 |
|
|
2019
Q1 | $230M | Sell |
2,849,560
-1,757,951
| -38% | -$144M | 0.03% | 429 |
|
|
2018
Q4 | $425M | Buy |
4,607,511
+281,296
| +7% | +$24.7M | 0.07% | 261 |
|
|
2018
Q3 | $409M | Sell |
4,326,215
-848,371
| -16% | -$80.5M | 0.06% | 310 |
|
|
2018
Q2 | $479M | Sell |
5,174,586
-889,660
| -15% | -$86.9M | 0.07% | 260 |
|
|
2018
Q1 | $574M | Sell |
6,064,246
-910,500
| -13% | -$100M | 0.09% | 226 |
|
|
2017
Q4 | $675M | Buy |
6,974,746
+303,472
| +5% | +$28.6M | 0.11% | 203 |
|
|
2017
Q3 | $593M | Buy |
6,671,274
+939,171
| +16% | +$71.5M | 0.1% | 214 |
|
|
2017
Q2 | $416M | Buy |
5,732,103
+216,810
| +4% | +$14.6M | 0.07% | 282 |
|
|
2017
Q1 | $359M | Sell |
5,515,293
-790,302
| -13% | -$49.7M | 0.07% | 295 |
|
|
2016
Q4 | $395M | Sell |
6,305,595
-268,546
| -4% | -$16.4M | 0.08% | 278 |
|
|
2016
Q3 | $415M | Buy |
6,574,141
+125,191
| +2% | +$8.1M | 0.08% | 258 |
|
|
2016
Q2 | $399M | Sell |
6,448,950
-1,387,886
| -18% | -$84.6M | 0.08% | 262 |
|
|
2016
Q1 | $448M | Sell |
7,836,836
-1,069,896
| -12% | -$59.6M | 0.1% | 239 |
|
|
2015
Q4 | $528M | Sell |
8,906,732
-5,021,216
| -36% | -$289M | 0.11% | 200 |
|
|
2015
Q3 | $758M | Sell |
13,927,948
-10,984,477
| -44% | -$715M | 0.17% | 144 |
|
|
2015
Q2 | $1.67B | Buy |
24,912,425
+6,345,049
| +34% | +$414M | 0.34% | 66 |
|
|
2015
Q1 | $1.09B | Buy |
18,567,376
+2,774,585
| +18% | +$168M | 0.22% | 115 |
|
|
2014
Q4 | $1.03B | Sell |
15,792,791
-281,604
| -2% | -$17.8M | 0.22% | 114 |
|
|
2014
Q3 | $928M | Buy |
16,074,395
+4,166,310
| +35% | +$231M | 0.2% | 122 |
|
|
2014
Q2 | $672M | Buy |
11,908,085
+2,886,871
| +32% | +$151M | 0.15% | 172 |
|
|
2014
Q1 | $464M | Sell |
9,021,214
-4,930,955
| -35% | -$249M | 0.1% | 238 |
|
|
2013
Q4 | $737M | Sell |
13,952,169
-208,813
| -1% | -$10.3M | 0.17% | 153 |
|
|
2013
Q3 | $633M | Buy |
14,160,982
+2,120,810
| +18% | +$94M | 0.16% | 168 |
|
|
2013
Q2 | $498M | Buy |
+12,040,172
| New | +$527M | 0.13% | 204 |
|
Other funds holding ABBV
VCM
VPM
T. Rowe Price Associates's ABBV Position: Q1 2026 in Review
T. Rowe Price Associates increased its AbbVie (ABBV) stake by 32% in Q1 2026, buying an estimated $705M and bringing the position to 13,003,989 shares worth $2.83B. The position accounts for 0.33% of the portfolio, ranked #55.
T. Rowe Price Associates first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.95B in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- T. Rowe Price Associates held 13,003,989 shares of AbbVie worth $2.83B as of Q1 2026.
- T. Rowe Price Associates bought 3,177,601 AbbVie shares in Q1 2026, an estimated $705M.
- AbbVie made up 0.33% of T. Rowe Price Associates's portfolio in Q1 2026, its #55 holding.
- T. Rowe Price Associates first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's AbbVie position peaked at $5.95B in Q1 2022.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.